Results 161 to 170 of about 12,272 (191)
Some of the next articles are maybe not open access.
Lipid lowering with PCSK9 inhibitors
Nature Reviews Cardiology, 2014Statins are the most-effective therapy currently available for lowering the LDL-cholesterol (LDL-C) level and preventing cardiovascular events. Additional therapies are necessary for patients who cannot reach the target LDL-C level when taking the maximum-tolerated dose of a statin.
Razvan T, Dadu, Christie M, Ballantyne
openaire +2 more sources
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Current Cardiology Reports, 2013Despite the efficacy of statin therapy, patients treated with these agents face substantial residual risk that is associated with achieved levels of LDL cholesterol (LDL-C). These observations suggest a potential benefit of additional strategies to promote further LDL-C reduction.
Rose Q, Do +2 more
openaire +2 more sources
Expanded Indication for PCSK9 Inhibitors
The Medical Letter on Drugs and TherapeuticsThe FDA has approved changes to the wording of the cardiovascular risk reduction indications for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab (Repatha) and alirocumab (Praluent). Both drugs are now approved to reduce the risk of major adverse cardiovascular events (MACE) in adults at increased risk for these events ...
openaire +2 more sources
Third generation PCSK9-inhibitors
European Heart Journal, 2023Ulrich Laufs +2 more
openaire +3 more sources
PCSK9 inhibitors: clinical evidence and implementation
Nature Reviews Cardiology, 2018The gene encoding PCSK9 was first identified and linked to the phenotype of familial hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role of PCSK9 in the regulation of LDL-receptor recycling and identified loss-of-function variants of PCSK9 that were associated with low circulating levels of LDL cholesterol (LDL-C ...
openaire +2 more sources
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque
Atherosclerosis, 2023Celestino Sardu +2 more
exaly
Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
Drug Discovery Today, 2022Kishor Mohanan, Shakir Ahamad
exaly
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
Life, 2021Aleksandra Gąsecka +2 more
exaly
PCSK9 inhibitors and cardiovascular outcomes
Expert Opinion on Biological Therapy, 2020Peter Bramlage +2 more
exaly
Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis
British Journal of Clinical Pharmacology, 2023Shenyin Zhu, Xiaofang Zhao
exaly